214 related articles for article (PubMed ID: 21734596)
1. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus.
Kalla R; Spiegel R; Claassen J; Bardins S; Hahn A; Schneider E; Rettinger N; Glasauer S; Brandt T; Strupp M
J Neuroophthalmol; 2011 Dec; 31(4):320-5. PubMed ID: 21734596
[TBL] [Abstract][Full Text] [Related]
2. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus.
Kalla R; Glasauer S; Büttner U; Brandt T; Strupp M
Brain; 2007 Sep; 130(Pt 9):2441-51. PubMed ID: 17664175
[TBL] [Abstract][Full Text] [Related]
3. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.
Strupp M; Schüler O; Krafczyk S; Jahn K; Schautzer F; Büttner U; Brandt T
Neurology; 2003 Jul; 61(2):165-70. PubMed ID: 12874393
[TBL] [Abstract][Full Text] [Related]
4. Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus.
Sprenger A; Zils E; Rambold H; Sander T; Helmchen C
Ann N Y Acad Sci; 2005 Apr; 1039():395-403. PubMed ID: 15826992
[TBL] [Abstract][Full Text] [Related]
5. Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.
Sprenger A; Rambold H; Sander T; Marti S; Weber K; Straumann D; Helmchen C
Neurology; 2006 Sep; 67(5):905-7. PubMed ID: 16966567
[TBL] [Abstract][Full Text] [Related]
6. Aminopyridines for the treatment of cerebellar and ocular motor disorders.
Strupp M; Kalla R; Glasauer S; Wagner J; Hüfner K; Jahn K; Brandt T
Prog Brain Res; 2008; 171():535-41. PubMed ID: 18718350
[TBL] [Abstract][Full Text] [Related]
7. No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.
Lorenz D; Hagen K; Ufer M; Cascorbi I; Deuschl G; Volkmann J
Neurology; 2006 Jun; 66(11):1753-5. PubMed ID: 16769957
[TBL] [Abstract][Full Text] [Related]
8. The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia.
Tsunemi T; Ishikawa K; Tsukui K; Sumi T; Kitamura K; Mizusawa H
J Neurol Sci; 2010 May; 292(1-2):81-4. PubMed ID: 20181362
[TBL] [Abstract][Full Text] [Related]
9. Dalfampridine in patients with downbeat nystagmus--an observational study.
Claassen J; Feil K; Bardins S; Teufel J; Spiegel R; Kalla R; Schneider E; Jahn K; Schniepp R; Strupp M
J Neurol; 2013 Aug; 260(8):1992-6. PubMed ID: 23589193
[TBL] [Abstract][Full Text] [Related]
10. A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus--effects on slowphase eye velocity, postural stability, locomotion and symptoms.
Claassen J; Spiegel R; Kalla R; Faldon M; Kennard C; Danchaivijitr C; Bardins S; Rettinger N; Schneider E; Brandt T; Jahn K; Teufel J; Strupp M; Bronstein A
J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1392-9. PubMed ID: 23813743
[TBL] [Abstract][Full Text] [Related]
11. The role of regularity and synchrony of cerebellar Purkinje cells for pathological nystagmus.
Glasauer S; Rössert C; Strupp M
Ann N Y Acad Sci; 2011 Sep; 1233():162-7. PubMed ID: 21950989
[TBL] [Abstract][Full Text] [Related]
12. Effect of chlorzoxazone in patients with downbeat nystagmus: a pilot trial.
Feil K; Claaßen J; Bardins S; Teufel J; Krafczyk S; Schneider E; Schniepp R; Jahn K; Kalla R; Strupp M
Neurology; 2013 Sep; 81(13):1152-8. PubMed ID: 23975871
[TBL] [Abstract][Full Text] [Related]
13. Modelling drug modulation of nystagmus.
Glasauer S; Rössert C
Prog Brain Res; 2008; 171():527-34. PubMed ID: 18718349
[TBL] [Abstract][Full Text] [Related]
14. Aminopyridine treatment in a patient with bilateral vestibular failure and cryptogenic downbeat nystagmus.
Spiegel R; Kalla R; Classen J; Bardins S; Anciães da Silva F; Farahmand P; Hahn A; Schneider E; Rettinger N; Jahn K; Brandt T; Strupp M
J Neuroophthalmol; 2012 Jun; 32(2):190. PubMed ID: 22487785
[No Abstract] [Full Text] [Related]
15. Effect of 4-aminopyridine on upbeat and downbeat nystagmus elucidates the mechanism of downbeat nystagmus.
Glasauer S; Strupp M; Kalla R; Büttner U; Brandt T
Ann N Y Acad Sci; 2005 Apr; 1039():528-31. PubMed ID: 15827015
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of 4-aminopyridine in patients with downbeat nystagmus.
Domínguez-Durán E; Mármol-Szombathy I; Baños-Roldán Ú; Sánchez-Gómez S
Acta Otorrinolaringol Esp (Engl Ed); 2020; 71(1):40-44. PubMed ID: 31078225
[TBL] [Abstract][Full Text] [Related]
17. Effect of 3,4-diaminopyridine on the gravity dependence of ocular drift in downbeat nystagmus.
Helmchen C; Sprenger A; Rambold H; Sander T; Kömpf D; Straumann D
Neurology; 2004 Aug; 63(4):752-3. PubMed ID: 15326263
[No Abstract] [Full Text] [Related]
18. Beneficial effects of 3,4-diaminopyridine on positioning downbeat nystagmus in a circumscribed uvulo-nodular lesion.
Helmchen C; Gottschalk S; Sander T; Trillenberg P; Rambold H; Sprenger A
J Neurol; 2007 Aug; 254(8):1126-8. PubMed ID: 17410325
[No Abstract] [Full Text] [Related]
19. 18F-fluorodeoxyglucose hypometabolism in cerebellar tonsil and flocculus in downbeat nystagmus.
Bense S; Best C; Buchholz HG; Wiener V; Schreckenberger M; Bartenstein P; Dieterich M
Neuroreport; 2006 Apr; 17(6):599-603. PubMed ID: 16603919
[TBL] [Abstract][Full Text] [Related]
20. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
